Clinical Trial Update: A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease [Phase 1]

View source ↗

Summary

A Phase 1 study assessing whether intravenous risankizumab alters the pharmacokinetics of cytochrome P450 substrates in adults with moderately to severely activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Ulcerative Colitis (UC), Crohn's Disease | Phase 1 | Status: COMPLETED